These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29577600)

  • 1. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
    Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
    Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
    Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
    Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
    Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma].
    Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
    Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
    Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
    Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
    Seckinger A; Hillengass J; Emde M; Beck S; Kimmich C; Dittrich T; Hundemer M; Jauch A; Hegenbart U; Raab MS; Ho AD; Schönland S; Hose D
    Front Immunol; 2018; 9():1676. PubMed ID: 30079070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
    Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
    Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
    Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
    Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.
    Morandi F; Horenstein AL; Costa F; Giuliani N; Pistoia V; Malavasi F
    Front Immunol; 2018; 9():2722. PubMed ID: 30546360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis.
    Matsuda M; Gono T; Shimojima Y; Hoshii Y; Ikeda S
    Amyloid; 2003 Jun; 10(2):110-6. PubMed ID: 12964418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
    Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
    Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.